Tuberculosis Drug Discovery and Development 2019

• Other Authors: Riccardi, Giovanna (Editor), Sala, Claudia (Editor)
• Format: Electronic Book Chapter
• Language: English
• Published: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
• Subjects: Research & information: general; Biology, life sciences; mycobacteria; tuberculosis; multi-drug resistance; drug discovery; promiscuous targets; Mycobacterium tuberculosis; rifampin; isoniazid; mechanisms of resistance; mutations; granulomas; caseum; cell envelope; dormancy; delpazolid; macozinone; DprE1 inhibitor; clinical studies; discovery; mode of action; drug resistance; toxicity; target; energy metabolism; electron transport chain; oxidative phosphorylation; bedaquiline; Q203; MID3; pharmacokinetics; pharmacodynamics; drug-drug interactions; in vitro; in vivo; drug development; tuberculosis treatment; biomarkers; drug combination; clinical trial; BCG; tuberculosis vaccines; TBVI; EDCTP; IAVI; CTVD; host-directed therapy; anti-virulence compounds; TB; post-treatment sequelae; surgery; pulmonary rehabilitation; Carlo Forlanini; artificial pneumothorax; n/a; structure-based drug design; target-based drug design; PknB; PknG; DNA gyrase; antibiotic; mycobacterium; genomics; transcriptomics; proteomics; metabolomics; lipidomics; target identification; mechanism of action; antimicrobial drug resistance (AMR); target-based screening; phenotypic screening; antituberculosis agents; antimycobacterial; anti-TB drug pipeline; privileged targets; lead generation
• Online Access: DOAB: download the publication; DOAB: description of the publication

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis and still represents one of the global health threats to mankind. The World Health Organization estimated more than 10 million new cases and reported more than 1.5 million deaths in 2019, thus ranking TB among the main c...